FDA Approves Once-Weekly YUVIWEL® (navepegritide) for . . . “The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said
Yuviwel for Achondroplasia - WebMD Yuviwel increased growth rate across ages and genders However, the treatment difference between Yuviwel and placebo was larger in children aged 5 years or older than in those younger than 5 years
Yuviwel: Uses, Dosage, Side Effects, Warnings - Drugs. com Yuviwel is used to increase linear growth in children 2 years and older with achondroplasia with open epiphyses It is given once-weekly by subcutaneous injection Learn about side effects, the mechanism of action, and administration
Approval Label_219164Orig1s000lbl YUVIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses (1) This indication is approved under accelerated approval based on an improvement in annualized growth velocity Continued approval for this indication may be contingent upon verification and description of clinical
Navepegritide (Yuviwel®) for Children with Achondroplasia . . . Navepegritide (Yuviwel®) for Children with Achondroplasia: New Drugs and Therapeutics Written by Anna Ryabets-Lienhard, DO Edited by Neha Patel, DO and Emily Breidbart, MD On February 27th, 2026, the FDA approved Navepegritide (Yuviwel®), a C-natriuretic peptide (CNP) analog prodrug developed by Ascendis Pharmaceuticals using TransCon® CNP technology 1 The once‑weekly subcutaneous therapy
2026 Drug Approvals: Wegovy HD, Leucoverin, Plaque Psoriasis . . . FDA Drug Overview Yuviwel Drug Label Expanded Approval: Wellcovorin (Leucovorin Calcium) for Cerebral Folate Deficiency GSK’s Wellcovorin (leucovorin calcium) tablets were approved for the treatment of cerebral folate deficiency in adult and pediatric patients with a confirmed variant in the folate receptor 1 gene (CFD-FOLR1)
YUVIWEL - Ascendis Pharma Growth Disorders A S Trademark . . . Mark For: YUVIWEL™ trademark registration is intended to cover the categories of pharmaceutical preparations for the treatment of growth disorders; pharmaceutical preparations for the treatment of endocrine disorders; pharmaceutical preparations for the treatment of bone disorders; pharmaceutical preparations for the treatment of skeletal disorders; pharmaceutical preparations for the
FDA Approves YUVIWEL, a New Weekly Drug for Achondroplasia Experts view YUVIWEL as a significant advancement in achondroplasia treatment, offering a convenient once-weekly option with proven efficacy in improving growth velocity, though long-term benefits require further confirmation